| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 6,150 | 6,750 | 19:43 |
| Stück | Geld | Kurs | Brief | Stück |
|---|---|---|---|---|
| 35,000 | 6 | |||
| 33,000 | 33 | |||
| 11,000 | 500 | |||
| 9,500 | 175 | |||
| 8,550 | 450 | |||
| 7,000 | 69 | |||
| 6,900 | 69 | |||
| 6,800 | 69 | |||
| 6,750 | 1.813 | |||
Quelle: [URL] https://aktienkurs-orderbuch.finanznachrichten.de/88q.htm [/URL] | ||||
| 631 | 6,500 | |||
| 69 | 6,400 | |||
| 69 | 6,300 | |||
| 69 | 6,200 | |||
| 1.182 | 6,150 | |||
| 700 | 4,740 | |||
| 1.061 | 0,001 | |||
| Summe Aktien im Kauf | Verhältnis | Summe Aktien im Verkauf | ||
| 3.781 | 0,842 | 3.184 | ||
| Uhrzeit | Aktienkurs | Stück |
|---|---|---|
| 14:58:56 | 6,800 | 22 |
| 14:20:04 | 6,700 | 40 |
| 14:00:28 | 6,650 | 750 |
| 13:54:50 | 6,650 | 215 |
| Tagesumsatz Xetra | 0,000 0,00 % | 1.027 |
Angaben in grüner Schrift zeigen, dass der Aktienkurs im Vergleich zum vorherigen Kurs gestiegen ist. Angaben in roter Schrift zeigen gefallene Börsenkurse.
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Do | TRADING UPDATES: 4basebio fundraise; Geo Exploration secures grants | 4 | Alliance News | ||
| Do | 4basebio Plc - Proposed Retail Offer | 519 | PR Newswire | 4basebio Plc - Proposed Retail OfferPR NewswireLONDON, United Kingdom, October 15
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN WHOLE OR IN PART, TO US PERSONS... ► Artikel lesen | |
| Do | 4basebio Plc - Results of Capital Raise | 509 | PR Newswire | 4basebio Plc - Results of Capital RaisePR NewswireLONDON, United Kingdom, October 15
THIS ANNOUNCEMENT AND THE INFORMATION CONTAINED IN IT, IS RESTRICTED AND IS NOT FOR RELEASE, PUBLICATION... ► Artikel lesen | |
| 4BASEBIO Aktie jetzt für 0€ handeln | |||||
| Do | 4basebio Plc - Proposed Capital Raise of New Ordinary Shares to raise not less than £15 million | 239 | PR Newswire | 4basebio Plc - Proposed Capital Raise of New Ordinary Shares to raise not less than £15 millionPR NewswireLONDON, United Kingdom, October 15
THIS ANNOUNCEMENT AND THE INFORMATION CONTAINED... ► Artikel lesen | |
| 28.09. | 4basebio meldet starken Anstieg der Auftragseingänge bei sinkendem Umsatz | 55 | Investing.com Deutsch |
| Zeit | Aktuelle Nachrichten | Medien | ||
|---|---|---|---|---|
| 12:58 | BioNTech SE: BioNTech to Showcase Oncology Late-Stage Pipeline Progress and Pumitamig Novel-Novel Combination Data at ESMO 2026 | GlobeNewswire (Europe) | Late-breaking oral presentation will feature first data from the global ROSETTA Lung-107 Phase 2 clinical trial evaluating pumitamig, a PD-L1×VEGF-A bispecific immunomodulator, plus docetaxel in patients... ► Artikel lesen | |
| 12:58 | BioNTech SE: BioNTech präsentiert auf dem ESMO-Kongress 2026 Fortschritte ihrer spätklinischen Onkologie-Pipeline und Daten zu innovativen Kombinationsansätzen mit Pumitamig | GlobeNewswire (Deutschland) |
In einer Late-Breaking-Präsentation werden erste Daten aus der globalen klinischen Phase-2-Studie ROSETTA Lung-107 vorgestellt, in der Pumitamig, ein bispezifischer PD-L1×VEGF-A-Immunmodulatorkandidat... ► Artikel lesen | |
| 15:45 | PTA-PVR: Epigenomics AG: Veröffentlichung nach § 40 Abs. 1 WpHG | Dow Jones News | DJ PTA-PVR: Epigenomics AG: Veröffentlichung nach § 40 Abs. 1 WpHG
Veröffentlichung gem. -- 40 Abs. 1 WpHG
Epigenomics AG: Veröffentlichung nach -- 40 Abs. 1 WpHG
Heidelberg (pta000/19.10.2026/15:09... ► Artikel lesen | |
| 14:38 | OS Therapies: OS Therapies Announces Initial Closing of Warrant Exercise Inducement and Exchange Offer for Initial Gross Proceeds of Approximately $7.2 Million | Newsfile | Proceeds from the initial closing, together with accrued refundable U.K. R&D tax credits, expected to provide operating runway through major upcoming milestonesCompany expects to complete early market... ► Artikel lesen | |
| 14:36 | Tempus AI, Inc.: Tempus Presents Data Demonstrating AI-Enabled Pre-Screening Can Help Identify Patients for Biomarker Testing in NSCLC | Business Wire | Study presented at ESMO evaluated more than 60,000 advanced NSCLC cases and found greater than 80% sensitivity across all 12 biomarkers using routine H&E pathology images
Tempus AI, Inc. (NASDAQ:... ► Artikel lesen |